X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Strides Arcolab with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES SHASUN LTD vs DIVIS LABORATORIES - Comparison Results

STRIDES SHASUN LTD    Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES SHASUN LTD DIVIS LABORATORIES STRIDES SHASUN LTD/
DIVIS LABORATORIES
 
P/E (TTM) x 32.5 31.9 102.1% View Chart
P/BV x 0.9 5.2 16.8% View Chart
Dividend Yield % 1.1 1.0 119.0%  

Financials

 STRIDES SHASUN LTD   DIVIS LABORATORIES
EQUITY SHARE DATA
    STRIDES SHASUN LTD
Mar-17
DIVIS LABORATORIES
Mar-17
STRIDES SHASUN LTD/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,2751,222 104.3%   
Low Rs918784 117.1%   
Sales per share (Unadj.) Rs389.6153.1 254.4%  
Earnings per share (Unadj.) Rs28.039.9 70.0%  
Cash flow per share (Unadj.) Rs48.944.6 109.7%  
Dividends per share (Unadj.) Rs4.5010.00 45.0%  
Dividend yield (eoy) %0.41.0 41.2%  
Book value per share (Unadj.) Rs303.1201.8 150.2%  
Shares outstanding (eoy) m89.42265.47 33.7%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.86.6 43.0%   
Avg P/E ratio x39.225.1 156.1%  
P/CF ratio (eoy) x22.422.5 99.7%  
Price / Book Value ratio x3.65.0 72.8%  
Dividend payout %16.125.0 64.3%   
Avg Mkt Cap Rs m98,036266,266 36.8%   
No. of employees `0005.89.7 59.6%   
Total wages/salary Rs m5,8814,687 125.5%   
Avg. sales/employee Rs Th6,005.94,175.0 143.9%   
Avg. wages/employee Rs Th1,014.0481.5 210.6%   
Avg. net profit/employee Rs Th431.21,089.3 39.6%   
INCOME DATA
Net Sales Rs m34,83440,643 85.7%  
Other income Rs m1,686749 225.1%   
Total revenues Rs m36,52041,392 88.2%   
Gross profit Rs m6,42814,460 44.5%  
Depreciation Rs m1,8721,233 151.7%   
Interest Rs m2,26923 10,041.2%   
Profit before tax Rs m3,97313,953 28.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m40-   
Extraordinary Inc (Exp) Rs m-1,0060-   
Tax Rs m4703,349 14.0%   
Profit after tax Rs m2,50110,604 23.6%  
Gross profit margin %18.535.6 51.9%  
Effective tax rate %11.824.0 49.3%   
Net profit margin %7.226.1 27.5%  
BALANCE SHEET DATA
Current assets Rs m38,16540,105 95.2%   
Current liabilities Rs m30,4026,595 461.0%   
Net working cap to sales %22.382.5 27.0%  
Current ratio x1.36.1 20.6%  
Inventory Days Days77119 65.2%  
Debtors Days Days10481 129.5%  
Net fixed assets Rs m37,63919,995 188.2%   
Share capital Rs m894531 168.4%   
"Free" reserves Rs m26,21053,043 49.4%   
Net worth Rs m27,10553,574 50.6%   
Long term debt Rs m16,3770-   
Total assets Rs m81,16861,585 131.8%  
Interest coverage x2.8618.4 0.4%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.40.7 65.0%   
Return on assets %5.917.3 34.1%  
Return on equity %9.219.8 46.6%  
Return on capital %12.126.1 46.2%  
Exports to sales %00-   
Imports to sales %025.2 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA10,259 0.0%   
Fx inflow Rs m13,46535,384 38.1%   
Fx outflow Rs m4,07610,399 39.2%   
Net fx Rs m9,38924,985 37.6%   
CASH FLOW
From Operations Rs m2,88111,493 25.1%  
From Investments Rs m-7,051-11,372 62.0%  
From Financial Activity Rs m3,382-93 -3,632.9%  
Net Cashflow Rs m-78828 -2,773.1%  

Share Holding

Indian Promoters % 27.7 52.0 53.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 11.8 320.3%  
FIIs % 8.6 19.0 45.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 17.2 150.6%  
Shareholders   56,241 31,796 176.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES SHASUN LTD With:   ALKEM LABORATORIES  ABBOTT INDIA  FRESENIUS KABI ONCO.  STERLING BIOTECH  TORRENT PHARMA  

Compare STRIDES SHASUN LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (4QFY18); Net Profit Up 0.9%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.9% YoY). Sales on the other hand came in at Rs 11 bn (up 2.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES SHASUN LTD SHARE PRICE


Jun 22, 2018 (Close)

TRACK STRIDES SHASUN LTD

  • Track your investment in STRIDES SHASUN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES SHASUN LTD

STRIDES SHASUN LTD 8-QTR ANALYSIS

COMPARE STRIDES SHASUN LTD WITH

MARKET STATS